Logo do repositório

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy

dc.contributor.authorDias, Matheus Henrique
dc.contributor.authorFriskes, Anoek
dc.contributor.authorWang, Siying
dc.contributor.authorFernandes Neto, Joao M.
dc.contributor.authorvan Gemert, Frank
dc.contributor.authorMourragui, Soufiane
dc.contributor.authorPapagianni, Chrysa
dc.contributor.authorKuiken, Hendrik J.
dc.contributor.authorMainardi, Sara
dc.contributor.authorAlvarez-Villanueva, Daniel
dc.contributor.authorLieftink, Cor
dc.contributor.authorMorris, Ben
dc.contributor.authorDekker, Anna
dc.contributor.authorvan Dijk, Emma
dc.contributor.authorWilms, Lieke H. S.
dc.contributor.authorda Silva, Marcelo S. [UNESP]
dc.contributor.authorJansen, Robin A.
dc.contributor.authorMulero-Sánchez, Antonio
dc.contributor.authorMalzer, Elke
dc.contributor.authorVidal, August
dc.contributor.authorSantos, Cristina
dc.contributor.authorSalazar, Ramón
dc.contributor.authorWailemann, Rosangela A. M.
dc.contributor.authorTorres, Thompson E. P.
dc.contributor.authorDe Conti, Giulia
dc.contributor.authorRaaijmakers, Jonne A.
dc.contributor.authorSnaebjornsson, Petur
dc.contributor.authorYuan, Shengxian
dc.contributor.authorQin, Wenxin
dc.contributor.authorKovach, John S.
dc.contributor.authorArmelin, Hugo A.
dc.contributor.authorRiele, Hein Te
dc.contributor.authorvan Oudenaarden, Alexander
dc.contributor.authorJin, Haojie
dc.contributor.authorBeijersbergen, Roderick L.
dc.contributor.authorVillanueva, Alberto
dc.contributor.authorMedema, Rene H.
dc.contributor.authorBernards, Rene
dc.contributor.institutionThe Netherlands Cancer Institute
dc.contributor.institutionShanghai Jiao Tong University School of Medicine
dc.contributor.institutionHubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences) and University Medical Center
dc.contributor.institutionL’Hospitalet del Llobregat
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionL’Hospitalet de Llobre-gat
dc.contributor.institutionParc Cientific de Barcelona (PCB)
dc.contributor.institutionCIBERONC
dc.contributor.institutionInstituto Butantan
dc.contributor.institutionFaculty of Medicine
dc.contributor.institutionEastern Hepatobiliary Surgery Hospital
dc.contributor.institutionInc.
dc.date.accessioned2025-04-29T20:05:46Z
dc.date.issued2024-07-01
dc.description.abstractCancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor-suppressive resistance.en
dc.description.affiliationDivision of Molecular Carcinogenesis Oncode Institute The Netherlands Cancer Institute
dc.description.affiliationDivision of Cell Biology Oncode Institute The Netherlands Cancer Institute
dc.description.affiliationState Key Laboratory of Oncogenes and Related Genes Shanghai Cancer Institute Renji Hospital Shanghai Jiao Tong University School of Medicine
dc.description.affiliationDivision of Tumor Biology and Immunology The Netherlands Cancer Institute
dc.description.affiliationHubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences) and University Medical Center
dc.description.affiliationDivision of Molecular Carcinogenesis The Netherlands Cancer Institute
dc.description.affiliationChemoresistance and Predictive Factors Group Program Against Cancer Therapeutic Resistance (ProCURE) Catalan Institute of Oncology (ICO) Oncobell Program Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet del Llobregat
dc.description.affiliationDivision of Molecular Carcinogenesis NKI Robotic and Screening Center The Netherlands Cancer Institute
dc.description.affiliationDepartment of Biochemistry Institute of Chemistry University of São Paulo, SP
dc.description.affiliationDepartment of Chemical and Biological Sciences Institute of Biosciences São Paulo State University (UNESP), SP
dc.description.affiliationDepartment of Pathology University Hospital of Bellvitge Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet de Llobre-gat
dc.description.affiliationXenopat S.L. Parc Cientific de Barcelona (PCB)
dc.description.affiliationDepartment of Medical Oncology Catalan Institute of Oncology (ICO) Oncobell Program Bellvitge Biomedical Research Institute (IDIBELL) CIBERONC
dc.description.affiliationCenter of Toxins Immune-response and Cell Signaling Instituto Butantan
dc.description.affiliationDepartment of Clinical and Experimental Oncology Federal University of São Paulo (UNIFESP)
dc.description.affiliationDepartment of Pathology The Netherlands Cancer Institute
dc.description.affiliationUniversity of Iceland Faculty of Medicine
dc.description.affiliationThe Third Department of Hepatic Surgery Eastern Hepatobiliary Surgery Hospital
dc.description.affiliationLixte Biotechnology Holdings Inc.
dc.description.affiliationUnespDepartment of Chemical and Biological Sciences Institute of Biosciences São Paulo State University (UNESP), SP
dc.description.sponsorshipEuropean Research Council
dc.description.sponsorshipGeneralitat de Catalunya
dc.description.sponsorshipNational Natural Science Foundation of China
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipInstituto de Salud Carlos III
dc.description.sponsorshipIdGeneralitat de Catalunya: 2017SGR449
dc.description.sponsorshipIdGeneralitat de Catalunya: 2021 SGR 00184
dc.description.sponsorshipIdNational Natural Science Foundation of China: 22XD1423100
dc.description.sponsorshipIdFAPESP: 82222047
dc.description.sponsorshipIdInstituto de Salud Carlos III: PI19-01320
dc.description.sponsorshipIdInstituto de Salud Carlos III: PI22-00548
dc.format.extent1276-1301
dc.identifierhttp://dx.doi.org/10.1158/2159-8290.CD-23-0216
dc.identifier.citationCancer Discovery, v. 14, n. 7, p. 1276-1301, 2024.
dc.identifier.doi10.1158/2159-8290.CD-23-0216
dc.identifier.issn2159-8290
dc.identifier.issn2159-8274
dc.identifier.scopus2-s2.0-85190311153
dc.identifier.urihttps://hdl.handle.net/11449/306263
dc.language.isoeng
dc.relation.ispartofCancer Discovery
dc.sourceScopus
dc.titleParadoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategyen
dc.typeArtigopt
dspace.entity.typePublication

Arquivos

Coleções